botensilimab
botensilimab: sourced relationships with 1 company · 19 clinical trials tracked.
botensilimab evidence translation
What we can confirm
19 tracked trials
What it means
What to watch
Prepared research question
How could botensilimab → AGEN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AGENUS INC (AGEN) Advanced Renal Cell Carcinoma; Advanced Cancer; Metastatic P… | Phase 2 |
Clinical Trial Registry Records (19)showing 10 most recent
A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
Primary endpoint: Two-year disease-free survival rate
A Phase 2 Study of the Safety and Efficacy of Neoadjuvant Botensilimab in Combination With Balstilimab in the Treatment of Microsatellite Stable / Mismatch Repair Proficient Early Rectal Cancer (RECTIFY-1)
Primary endpoint: Complete response (cCR plus nCR with pCR at resection) within 6 months from initiation of therapy or nCR with pathologic complete response (pCR) with TES
A Pilot Study of Botensilimab and Balstilimab and SBRT in Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
Primary endpoint: Incidence of dose limiting radiation-related toxicities
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Primary endpoint: Overall Survival
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)
Primary endpoint: Survival of patients
Phase II Study of Adjuvant Botensilimab in Combination With Balstilimab in Patients With Colorectal Cancer and Persistent Circulating Tumor DNA Following Surgery and Chemotherapy
Primary endpoint: Rate of ctDNA clearance (Cohort 1a)
A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Primary endpoint: Clinical Benefit Rate (CBR)
Phase II Clinical Trial of FOLFOX, Botensilimab, Plus Balstilimab in Patients With Localized Rectal Cancer
Primary endpoint: Complete clinical response (cCR) rate
A Phase II Study of Neoadjuvant Botensilimab and Balstilimab Immunotherapy for Mismatch Repair Proficient Rectal Adenocarcinoma
Primary endpoint: Best Overall Response Rate
An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer
Primary endpoint: Maximum Tolerated Dose (MTD)
Frequently asked questions
Which companies have sourced relationships with botensilimab?
botensilimab has dated SEC/FDA relationship records for AGENUS INC.
How many clinical trials involve botensilimab?
BioSniper tracks 19 clinical trials involving botensilimab.